Evaluation serum soluble interleukin 2 receptor with diagnosis and prognosis in canine solid tumour: 34 cases.
dog
malignant tumour
soluble interlukin‐2 receptor
tumour biomarker
Journal
Veterinary medicine and science
ISSN: 2053-1095
Titre abrégé: Vet Med Sci
Pays: England
ID NLM: 101678837
Informations de publication
Date de publication:
Sep 2024
Sep 2024
Historique:
revised:
24
04
2024
received:
01
04
2023
accepted:
10
06
2024
medline:
17
9
2024
pubmed:
17
9
2024
entrez:
17
9
2024
Statut:
ppublish
Résumé
The soluble interleukin-2 receptor (sIL-2R) serve as a valuable biomarker for tumors in human patients, as its levels increase during the activation of T lymphocytes in clinical states such as inflammation, infection, and tumor. This study aimed to demonstrate that sIL-2R levels can be also elevated in dogs with tumors and evaluate its applicability as a diagnostic and prognostic factor in canine cancer patients. Serum was collected from 6 healthy dogs and 34 dogs with solid tumors. The concentration of sIL-2R was measured using a commercial enzyme-linked immunosorbent assay kit. The median sIL-2R concentration was significantly higher in dogs with solid masses than in healthy dogs (117.3 vs 68.33 pg/ml, p = 0.016). The highest median sIL-2R concentration was found in dogs with malignant tumors, followed by those with benign tumors, and healthy dogs (119.6 vs 93.74 vs 68.33 pg/ml, respectively). In dogs with malignant tumors, the mortality rate was significantly higher in the group with high sIL-2R levels than in the group with low sIL-2R levels. Dogs with solid tumors, particularly those with malignant tumors, had higher concentrations of sIL-2R than healthy dogs. Among dogs with malignant tumors, a correlation between sIL-2R concentration and mortality rate was confirmed. Serum sIL-2R levels may be used to detect malignant tumors and serve as a prognostic factor in dogs with malignant tumors.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
The soluble interleukin-2 receptor (sIL-2R) serve as a valuable biomarker for tumors in human patients, as its levels increase during the activation of T lymphocytes in clinical states such as inflammation, infection, and tumor. This study aimed to demonstrate that sIL-2R levels can be also elevated in dogs with tumors and evaluate its applicability as a diagnostic and prognostic factor in canine cancer patients.
PATIENTS AND METHODS
METHODS
Serum was collected from 6 healthy dogs and 34 dogs with solid tumors. The concentration of sIL-2R was measured using a commercial enzyme-linked immunosorbent assay kit.
RESULTS
RESULTS
The median sIL-2R concentration was significantly higher in dogs with solid masses than in healthy dogs (117.3 vs 68.33 pg/ml, p = 0.016). The highest median sIL-2R concentration was found in dogs with malignant tumors, followed by those with benign tumors, and healthy dogs (119.6 vs 93.74 vs 68.33 pg/ml, respectively). In dogs with malignant tumors, the mortality rate was significantly higher in the group with high sIL-2R levels than in the group with low sIL-2R levels. Dogs with solid tumors, particularly those with malignant tumors, had higher concentrations of sIL-2R than healthy dogs. Among dogs with malignant tumors, a correlation between sIL-2R concentration and mortality rate was confirmed.
CONCLUSION
CONCLUSIONS
Serum sIL-2R levels may be used to detect malignant tumors and serve as a prognostic factor in dogs with malignant tumors.
Substances chimiques
Receptors, Interleukin-2
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e70033Informations de copyright
© 2024 The Author(s). Veterinary Medicine and Science published by John Wiley & Sons Ltd.
Références
Bien, E., & Balcerska, A. (2008). Serum soluble interleukin 2 receptor α in human cancer of adults and children: A review. Biomarkers, 13(1), 1–26..
Boyano, M. D., Garcia‐Vázquez, M. D., López‐Michelena, T., Gardeazabal, J., Bilbao, J., Cañavate, M. L., Galdeano, A. G., Izu, R., Díaz‐Ramón, L., Raton, J. A., & Díaz‐Pérez, J. L. (2000). Soluble interleukin‐2 receptor, intercellular adhesion molecule‐1 and interleukin‐10 serum levels in patients with melanoma. British Journal of Cancer, 83(7), 847–852..
Brawley, O. W., & Kramer, B. S. (2005). Cancer screening in theory and in practice. Journal of Clinical Oncology, 23(2), 293–300..
Colombe, P., Béguin, J., Benchekroun, G., & Le Roux, D. (2022). Blood biomarkers for canine cancer, from human to veterinary oncology. Veterinary and Comparative Oncology, 20(4), 767–777..
Correia, O., Delgado, L., Roujeau, J.‐C., Le Cleach, L., & Fleming‐Torrinha, J. A. (2002). Soluble interleukin 2 receptor and interleukin 1α in toxic epidermal necrolysis: A comparative analysis of serum and blister fluid samples. Archives of Dermatology, 138(1), 29–32..
Da, M., Ruscetti, F. W., & Gallo, R. (1976). Selective in vitro growth of T lymphocytes from normal human bone marrows. Science, 193(4257), 1007–1008..
Gebauer, G., Rieger, M., Jäger, W., & Lang, N. (1999). Prognostic relevance of soluble interleukin‐2 receptors in patients with ovarian tumors. Anticancer Research, 19(4A), 2509–2511..
Goto, H., Tsurumi, H., Takemura, M., Ino‐Shimomura, Y., Kasahara, S., Sawada, M., Yamada, T., Hara, T., Fukuno, K., Goto, N., Okuno, M., Takami, T., Seishima, M., & Moriwaki, H. (2005). Serum‐soluble interleukin‐2 receptor (sIL‐2R) level determines clinical outcome in patients with aggressive non‐Hodgkin's lymphoma: In combination with the International Prognostic Index. Journal of Cancer Research and Clinical Oncology, 131, 73–79..
Heaney, M. L., & Golde, D. W. (1998). Soluble receptors in human disease. Journal of Leukocyte Biology, 64(2), 135–146..
Henry, C. J. (2010). Biomarkers in veterinary cancer screening: Applications, limitations and expectations. The Veterinary Journal, 185(1), 10–14..
Im, J. H., Park, S. M., An, J. H., Kim, T. H., Chae, H. K., Oh, Y. I., Seo, K. W., & Youn, H. Y. (2023). Evaluation of serum interleukin 2 receptor and beta‐2‐microglobulin as prognostic factors for canine lymphoma: A pilot study. Veterinary and Comparative Oncology, 21(2), 184–190..
Kawashima, O., Kamiyoshihara, M., Sakata, S., Endo, K., Saito, R., & Morishita, Y. (2000). The clinicopathological significance of preoperative serum‐soluble interleukin‐2 receptor concentrations in operable non‐small‐cell lung cancer patients. Annals of Surgical Oncology, 7, 239–245..
Klein, B., Levin, I., Kfir, B., Mishaeli, M., Shapira, J., & Klein, T. (1995). The significance of soluble interleukin‐2, soluble interleukin‐2 receptors, soluble ICAM‐1 and β2‐microglobulin in breast cancer patients. Tumor Biology, 16(5), 290–296..
Lissoni, P., Barni, S., Rovelli, F., Viviani, S., Maestroni, G. J., Conti, A., & Tancini, G. (1990). The biological significance of soluble interleukin‐2 receptors in solid tumors. European Journal of Cancer and Clinical Oncology, 26(1), 33–36.
Mariotti, S., Barbesino, G., Caturegli, P., Marinò, M., Manetti, L., Fugazzola, L., Pacini, F., & Pinchera, A. (1994). Serum soluble interleukin 2 (IL‐2) receptor (sIL‐2R) in differentiated thyroid carcinoma. Journal of Endocrinological Investigation, 17(11), 861–867..
Meyer, A., Gruber, A., & Klopfleisch, R. (2013). All subunits of the interleukin‐2 receptor are expressed by canine cutaneous mast cell tumours. Journal of Comparative Pathology, 149(1), 19–29..
Mizutani, N., Goto‐Koshino, Y., Kurata, K., Fujiwara‐Igarashi, A., Sakaguchi, M., Asada, M., Ohno, K., & Tsujimoto, H. (2020). Measurement of the concentration of serum soluble interleukin‐2 receptor alpha chain in dogs with lymphoma. Veterinary Immunology and Immunopathology, 225, 110054..
Morris, J. C., & Waldmann, T. A. (2000). Advances in interleukin 2 receptor targeted treatment. Annals of the Rheumatic Diseases, 59(Suppl 1), i109–i114.
Murakami, S. (2004). Soluble interleukin‐2 receptor in cancer. Frontiers in Bioscience‐Landmark, 9(5), 3085–3090.
Murakami, S., Sakata, H., Tsuji, Y., Okubo, K., Hamada, S., & Hirayama, R. (2002). Serum soluble interleukin‐2 receptor as a predictor of lymph node metastasis in early gastric cancer. Digestive Surgery, 19(1), 9–14..
Nakase, K., Tsuji, K., Tamaki, S., Tanigawa, M., Ikeda, T., Miyanishi, E., & Shiku, H. (2005). Elevated levels of soluble interleukin‐2 receptor in serum of patients with hematological or non‐hematological malignancies. Cancer Detection and Prevention, 29(3), 256–259..
Orditura, M., De Vita, F., Roscigno, A., Auriemma, A., Infusino, S., & Catalano, G. (1998). Soluble interleukin‐2 receptor and soluble CD8 antigen levels in serum from patients with solid tumors. International Journal of Molecular Medicine, 2(1), 75–84..
Pawlaczyk, M., & Sobieska, M. (2006). A correlation between acute phase proteins and cytokines in patients suffering from mycosis fungoides. Acta Dermatovenerologica Alpina Pannonica et Adriatica, 15(3), 107–112.
Pinho, S. S., Carvalho, S., Cabral, J., Reis, C. A., & Gärtner, F. (2012). Canine tumors: A spontaneous animal model of human carcinogenesis. Translational Research, 159(3), 165–172..
Rimoldi, D., Salvi, S., Hartmann, F., Schreyer, M., Blum, S., Zografos, L., Plaisance, S., Azzarone, B., & Carrel, S. (1993). Expression of IL‐2 receptors in human melanoma cells. Anticancer Research, 13(3), 555–564..
Rutkowski, P., Kaminska, J., Kowalska, M., Ruka, W., & Steffen, J. (2002). Cytokine serum levels in soft tissue sarcoma patients: Correlations with clinico‐pathological features and prognosis. International Journal of Cancer, 100(4), 463–471..
Tartour, E., Deneux, L., Mosseri, V., Jaulerry, C., Brunin, F., Point, D., Validire, P., Dubray, B., Fridman, W. H., & Rodriguez, J. (1997). Soluble interleukin‐2 receptor serum level as a predictor of locoregional control and survival for patients with head and neck carcinoma: Results of a multivariate prospective study. Cancer: Interdisciplinary International Journal of the American Cancer Society, 79(7), 1401–1408.
Tartour, E., Mosseri, V., Jouffroy, T., Deneux, L., Jaulerry, C., Brunin, F., Fridman, W. H., & Rodriguez, J. (2001). Serum soluble interleukin–2 receptor concentrations as an independent prognostic marker in head and neck cancer. The Lancet, 357(9264), 1263–1264.
Trentin, L., Zambello, R., Bulian, P., Cerutti, A., Milani, A., Pirone, E., Nitti, D., Agostini, C., & Semenzato, G. (1994). Functional role of IL‐2 receptors on tumour‐infiltrating lymphocytes. British Journal of Cancer, 69(6), 1046–1051..
Wang, L.‐S., Chow, K.‐C., Li, W.‐Y., Liu, C.‐C., Wu, Y.‐C., & Huang, M.‐H. (2000). Clinical significance of serum soluble interleukin 2 receptor‐α in esophageal squamous cell carcinoma. Clinical Cancer Research, 6(4), 1445–1451..
Withrow, S. J., Vail, D. M., & Page, R. L. (2013). Withrow and MacEwen's small animal clinical oncology‐E‐book. Elsevier Health Sciences.
Witkowska, A. M. (2005). On the role of sIL‐2R measurements in rheumatoid arthritis and cancers. Mediators of Inflammation, 2005(3), 121–130..
Yano, T., Fukuyama, Y., Yokoyama, H., Takai, E., Tanaka, Y., Asoh, H., & Ichinose, Y. (1996). Interleukin‐2 receptors in pulmonary adenocarcinoma tissue. Lung Cancer, 16(1), 13–19.